These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 16840379

  • 1. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
    Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK.
    Chest; 2006 Jul; 130(1):30-6. PubMed ID: 16840379
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
    Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ.
    J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
    Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK.
    Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.
    Clin Exp Rheumatol; 2016 Nov; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [Abstract] [Full Text] [Related]

  • 5. [Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease].
    Zhang G, Xu T, Zhang H, Ye S, Wang Q, Zhang L, Lei Y, Luo R, Zhang X.
    Zhonghua Yi Xue Za Zhi; 2015 Dec 01; 95(45):3641-5. PubMed ID: 26849923
    [Abstract] [Full Text] [Related]

  • 6. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects.
    Saketkoo LA, Espinoza LR.
    Am J Med Sci; 2009 May 01; 337(5):329-35. PubMed ID: 19295413
    [Abstract] [Full Text] [Related]

  • 7. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
    Int J Rheum Dis; 2014 Nov 01; 17(8):923-8. PubMed ID: 24864029
    [Abstract] [Full Text] [Related]

  • 8. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S.
    Arthritis Res Ther; 2016 Jun 02; 18(1):123. PubMed ID: 27255492
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.
    Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH.
    PLoS One; 2017 Jun 02; 12(5):e0177107. PubMed ID: 28542177
    [Abstract] [Full Text] [Related]

  • 10. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
    Chartrand S, Swigris JJ, Peykova L, Fischer A.
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan 15; 32(4):296-304. PubMed ID: 26847096
    [Abstract] [Full Text] [Related]

  • 11. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
    Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y.
    Respirology; 2018 Nov 15; 23(11):1041-1048. PubMed ID: 30011421
    [Abstract] [Full Text] [Related]

  • 12. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.
    Oldham JM, Lee C, Valenzi E, Witt LJ, Adegunsoye A, Hsu S, Chen L, Montner S, Chung JH, Noth I, Vij R, Strek ME.
    Respir Med; 2016 Dec 15; 121():117-122. PubMed ID: 27888985
    [Abstract] [Full Text] [Related]

  • 13. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK, Sharma SK, Adarsh MB, Dhir V, Sinha A, Dhooria S, Jain S.
    Rheumatol Int; 2020 Feb 15; 40(2):207-216. PubMed ID: 31813058
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
    Liossis SN, Bounas A, Andonopoulos AP.
    Rheumatology (Oxford); 2006 Aug 15; 45(8):1005-8. PubMed ID: 16490756
    [Abstract] [Full Text] [Related]

  • 15. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.
    Gerbino AJ, Goss CH, Molitor JA.
    Chest; 2008 Feb 15; 133(2):455-60. PubMed ID: 18071023
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.
    Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI.
    Clin Rheumatol; 2010 Oct 15; 29(10):1167-8. PubMed ID: 20532938
    [Abstract] [Full Text] [Related]

  • 17. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
    Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA.
    Respir Med; 2008 Jan 15; 102(1):150-5. PubMed ID: 17822892
    [Abstract] [Full Text] [Related]

  • 18. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
    Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.
    Trials; 2017 Jun 15; 18(1):275. PubMed ID: 28619061
    [Abstract] [Full Text] [Related]

  • 19. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.
    Arthritis Rheumatol; 2017 Jul 15; 69(7):1451-1460. PubMed ID: 28376288
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators.
    Lancet Respir Med; 2016 Sep 15; 4(9):708-719. PubMed ID: 27469583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.